AIM ImmunoTech Stock Gains Over Final Approval Of Novel Cancer Therapy Patent In Japan

Shares of AIM ImmunoTech Inc. (AIM) are climbing about 80 percent on Wednesday morning trading after the Japan Patent Office approved a Japanese patent covering the company's proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors for the treatment of cancer.The company's shares are currently trading at $1.28 on the New York Stock Exchange American, up 80.28 percent. The stock opened at $1.45 and has climbed as high as $1.62 so far in today's session. Over the past year, it has ...